Search
 
1    2    3    4   
Press Releases
May 26, 2015
Generex Announces Collaboration with NHTherapeutics to Utilize the RapidMist™ Buccal Delivery Technology for Leuprolide
May 14, 2015
Generex Provides Data Update from AE37 Phase II Breast Cancer Trial One Year Post Completion of Enrollment
May 04, 2015
Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split
All releases
Webcast Events and Media
  Generex Conference Call with Conference Call with Members of the Antigen Express Scientific Advisory Board
- Aug 14, 2013

 
  Generex Investor Conference Call
- Jan 31, 2013

  Second Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference at the New York Academy of Medicine
- Oct 06, 2011


Print Print     Email Email page

Investor Home


Investor Relations

For more information please contact:
Todd Falls
Tel: 1-800-391-6755
Fax: (647) 547-7104
Email: tfalls@generex.com


Exchange

OTC Bulletin Board

Listed Security

GNBT Common Stock

Transfer Agent

StockTrans, Inc.
44 West Lancaster Avenue
Ardmore, PA 19003
Phone 610-649-7300
Fax 610-649-7302

Corporate Counsel

Eckert Seamans Cherin & Mellott, LLC
1515 Market Street, 9th Floor
Philadelphia, PA 19102
Phone 215-851-8447
Fax 215-851-8383


Stock Quote
OTC BB: GNBT        0.02 + 0.00
26 May 2015    3:59 PM ET
Investor Tool Kit
PDF Corporate Fact Sheet
PDF Investor Presentation

Privacy Policy